Sg3 Management, LLC Akero Therapeutics, Inc. Transaction History
Sg3 Management, LLC
- $0
- Q3 2023
A detailed history of Sg3 Management, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Sg3 Management, LLC holds 30,000 shares of AKRO stock, worth $1.55 Million. This represents 0.24% of its overall portfolio holdings.
Number of Shares
30,000Holding current value
$1.55 Million% of portfolio
0.24%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding AKRO
# of Institutions
269Shares Held
86MCall Options Held
1.02MPut Options Held
823K-
Rtw Investments, LP New York, NY7.42MShares$382 Million4.92% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$364 Million0.16% of portfolio
-
Wellington Management Group LLP Boston, MA5.94MShares$306 Million0.05% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$288 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$270 Million7.15% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.39B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...